Sponsored by
Very exciting work.
The first 457 patient with recurrent gbms who used the Novocure NovoTTF-100a therapy after it was FDA approved were analyzed to see how they did. This is for people outside of the trials. Results were much better than the large trial that resulted in FDA approval.
There are 2 trials going on novocure device. One for newly diagnosed gbm and one for recurrent gbm. It is also available by prescription at over 100 major brain tumor centers (The advantage of entering the trials are the costs.)
I need everyone's help on this. In addition to raising awareness, this is a fundraiser that doesn't cost you any money. I need people to visit the website, and participate in the twitter and facebook campaign. Participation is free and easy.
For Twitter:
Go to twitter.com Log in (register if you do not have a twitter account) and search for the hashtag #tuneIn2GBM pick 2 of the tweets and retweet them (Just click the retweet button). Try to do that every day during May. And ask your friends to do the same.
For Facebook: Log in (or register) with facebook.com and go to:
https://www.facebook.com/Braintumor
Just click the LIKE or Follow button for the page and any articles from me, and also from the partners mentioned in the press release!
thanks
This is from our friendsat the Chris Elliott Fund. Sounds like a great event! It is free, but requires registration
Sounds interesting
Interesting - will be watching this as they apply it to people.
This project did not find a link between cytomegalovirus and brain tumors. However, they sensationalized the headline by saying brain tumors are not caused by viruses then went on to say antiviral therapy is misguided.
This is a very controversial subject. I have seen people who did well with antiviral drugs. Some researchers reported that all or almost all of the gbm samples they tested had the virus. It is possible that the virus does not cause the tumor but allows it to become more malignant and to evade the immune system. If true, then antivirals - or even vaccines against cytomegalovirus, make a lot of sense.
There has been a study on human trials of antivirals. Unfortunately the study was designed poorly. It had good results, but poorly designed studies are not considered proof that something works. What is needed is a better designed study. It may be impossible to do a gold standard phase 3 randomized double blinded trial because the drugs are expensive and the companies that make them are not interested in supporting brain tumor trials, so we may have to do it on our own in a virtual way. I am working on that.
This trial may be a good choice for GBM patients who have unmethylated MGMT
I need help with this - I am giving a lecture about speeding up clinical trial enrollment and need to know what the barriers are. Please take this quick survey - only 6 questions. Thanks!
This is a first for us: a BMX fundraiser! Sounds like fun!
Nice story on our National Walk To End Brain Tumors
This is for colorectal cancer but it shows that adding treatments doesn't always make things better. Even if it sounds like it makes sense and should work, cancer is a very complex disease and the only way to tell if something works is clinical trials
This is from our friends at the Chris Elliott Fund.
This may show how Gliolan works. It is a dye that makes the tumor light up during surgery - approved in Europe but not the USA.
Exciting approach. Not done in people yet, but I will be watching this one.
We need help raising money to fund brain tumor research! Go to http://WalkToEndBrainTumors.org and see if there is an event near you. If there is no event near you, contact us to help get one started. If there is an event near you, contact the event leader and volunteer to help promote the event!
Sounds interesting in theory - but a clinical trial is needed to test it. Should be easy because both components are fda approved for other things.
Keep in mind arsenic at the wrong dose can be fatal.
This phase 1 trial did better than expected (but that is only with the endpoint of safety and immune response, they did not mention survival in the article). Sounds like a great concept. They have an approach similiar to ICT-107 but with different targets. We will be keeping an eye on this one!
